NuVasive Announces Acquisition of Manufacturing Facility

NuVasive Announces Acquisition of Manufacturing Facility 
SAN DIEGO, CA -- (Marketwired) -- 05/06/13 --  NuVasive, Inc.
(NASDAQ: NUVA) 


 
--  Marks foray into full scale implant manufacturing
--  Creates long term opportunity to improve operating margin

  
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on
developing minimally disruptive surgical products and procedures for
the spine, announced today the acquisition of ANC, LLC, a spine
implant manufacturer based in Dayton, Ohio. 
NuVasive has been involved with the manufacturer since it was
established in May of 2010 as a manufacturing partner. The
relationship expanded over the past 3 years, and ANC is currently one
of NuVasive's significant implant suppliers.  
Alex Lukianov, Chairman and Chief Executive Officer, said, "We are
very excited to welcome ANC's 65 member team into the NuVasive
family. Over the past three years, we have been very impressed with
ANC's progression as a quality manufacturer and their cultural fit
with NuVasive. The facility will be designated NuVasive
Manufacturing, LLC, and we look forward to expanding their capacity
and systems as we grow together. Bringing portions of our
manufacturing in house is a key element of our ongoing commitment to
improve operating profitability as we grow toward $1 billion in
revenue and beyond. With Speed of Innovation as a fundamental
cornerstone of our success, the acquisition will reduce the time from
the concept of a new idea to ultimate market introduction, enabling
development and manufacturing to work seamlessly in launching our
innovative solutions." 
In total consideration for ANC, NuVasive will pay approximately $4.5
million. No debt will be assumed in the deal. The Company anticipates
the transaction will be neutral to earnings in fiscal year 2013. Over
the long term, however, the Company expects vertical integration will
provide opportunities to drive profitability improvements. 
About NuVasive 
NuVasive is an innovative global medical device company that is
changing spine surgery with minimally disruptive surgical products
and procedurally integrated solutions for the spine. The Company is
the 4th largest player in the $8.2 billion global spine market. 
NuVasive offers a comprehensive spine portfolio of over 80 unique
products developed to improve spine surgery and patient outcomes. The
Company's principal procedural solution is its Maximum Access
Surgery, or MAS(R) platform for lateral spine fusion. MAS provides
safe, reproducible, and clinically proven outcomes, and is a highly
differentiated solution with fully integrated neuromonitoring,
customizable exposure, and a broad offering of application-specific
implants and fixation devices designed to address a variety of
pathologies.  
Having pioneered the lateral approach to spine fusion, NuVasive
continues to be at the forefront of the spine industry's shift toward
less invasive solutions. The Company places a large focus on clinical
research and support of the Society of Lateral Access Surgery, or
SOLAS(R), to expand the body of clinical evidence in support of
NuVasive's minimally disruptive solutions and to drive adoption of
its techniques. The Company's dedication to innovation continues to
spawn game changing technology such as the PCM(R) motion preserving
disc for the cervical spine, XLIF(R) Corpectomy for tumor and trauma,
and Armada(R), which treats adult degenerative scoliosis in a less
invasive fashion. The Company has also developed procedural solutions
that completely redefine and improve upon traditional procedures like
TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are
increasingly being adopted internationally, as the Company lays the
groundwork to continue growing as a global business and to offer
industry-leading, Absolutely Responsive customer service to surgeons
world-wide. NuVasive is focused on becoming a $1 Billion
Start-Up(TM); taking market share by maintaining a commitment to
Superior Clinical Outcomes, Speed of Innovation(R), and Absolute
Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
risk that NuVasive's revenue or earnings projections may turn out to
be inaccurate because of the preliminary nature of the forecasts; the
risk of further adjustment, or unanticipated difficulty in selling
products or generating expected profitability; and other risks and
uncertainties more fully described in NuVasive's press releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange Commission
are available at www.sec.gov. NuVasive assumes no obligation to
update any forward-looking statement to reflect events or
circumstances arising after the date on which it was made. 
Investor Contact:
Tina Jacobsen, CFA
NuVasive, Inc.
858-320-5215
investorrelations@nuvasive.com 
Media Contact: 
Nicole Collins
NuVasive, Inc.
858-909-1907
media@nuvasive.com 
 
 
Press spacebar to pause and continue. Press esc to stop.